Clinical Trials Logo
  1. Home
  2. Muscle Invasive Bladder Cancer
  3. NCT03732677

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC — NIAGARA  

Muscle Invasive Bladder Cancer Clinical Trial

Official title:
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.

Clinical Trial Summary

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03732677
Study type Interventional
Source AstraZeneca
Contact
Status Active, not recruiting
Phase Phase 3
Start date November 16, 2018
Completion date June 30, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04101812 - Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer Phase 2
Active, not recruiting NCT02546661 - Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer Phase 1
Terminated NCT02716896 - Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer N/A
Recruiting NCT04047693 - Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma Phase 2
Recruiting NCT02648100 - Basal Like Bladder Cancer : Signature and Therapeutic N/A
Terminated NCT03397394 - Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Phase 2
Recruiting NCT05236218 - To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
Active, not recruiting NCT04730219 - Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma Phase 2
Completed NCT03294304 - BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy Phase 2
Completed NCT03773666 - A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Phase 1
Completed NCT01031420 - Dose Dense MVAC for Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT04813107 - A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT03747419 - Avelumab and Radiation in Muscle-Invasive Bladder Cancer Phase 2
Recruiting NCT04960709 - Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin Phase 3
Not yet recruiting NCT05860543 - Clinical Performance Evaluation of the C2i Test
Recruiting NCT05979740 - RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Phase 2
Active, not recruiting NCT04053101 - Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer